G1 Therapeutics (NASDAQ:GTHX) Rating Reiterated by HC Wainwright

HC Wainwright reissued their buy rating on shares of G1 Therapeutics (NASDAQ:GTHX) in a report issued on Thursday, Benzinga reports. HC Wainwright currently has a $9.00 target price on the stock. HC Wainwright also issued estimates for G1 Therapeutics’ FY2026 earnings at $0.72 EPS.

Other equities research analysts have also issued research reports about the stock. Wedbush reissued an outperform rating and set a $5.00 target price (up previously from $4.00) on shares of G1 Therapeutics in a research note on Wednesday, February 28th. Needham & Company LLC reissued a buy rating and set a $12.00 price objective on shares of G1 Therapeutics in a research report on Wednesday.

G1 Therapeutics Price Performance

G1 Therapeutics stock traded up $0.05 during midday trading on Thursday, hitting $4.49. The company’s stock had a trading volume of 574,426 shares, compared to its average volume of 665,254. G1 Therapeutics has a 12 month low of $1.08 and a 12 month high of $5.00. The company has a quick ratio of 3.45, a current ratio of 2.94 and a debt-to-equity ratio of 1.34. The company has a market capitalization of $234.74 million, a PE ratio of -7.24 and a beta of 1.71. The stock’s 50-day moving average price is $3.90 and its 200-day moving average price is $3.06.

G1 Therapeutics (NASDAQ:GTHX) last posted its quarterly earnings data on Wednesday, May 1st. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The firm had revenue of $14.48 million for the quarter, compared to analysts’ expectations of $15.21 million. G1 Therapeutics had a negative return on equity of 74.75% and a negative net margin of 36.40%. During the same quarter in the previous year, the firm posted ($0.53) earnings per share. Analysts anticipate that G1 Therapeutics will post -0.64 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Rajesh Malik sold 28,600 shares of G1 Therapeutics stock in a transaction on Monday, February 12th. The shares were sold at an average price of $4.62, for a total value of $132,132.00. Following the completion of the sale, the insider now owns 169,938 shares of the company’s stock, valued at approximately $785,113.56. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 8.23% of the company’s stock.

Institutional Trading of G1 Therapeutics

Large investors have recently modified their holdings of the company. Curi Wealth Management LLC boosted its position in shares of G1 Therapeutics by 17.8% in the third quarter. Curi Wealth Management LLC now owns 70,742 shares of the company’s stock valued at $102,000 after acquiring an additional 10,700 shares during the period. Financial Advocates Investment Management acquired a new stake in G1 Therapeutics in the 4th quarter worth $39,000. Creative Financial Designs Inc. ADV increased its holdings in shares of G1 Therapeutics by 98.1% during the 4th quarter. Creative Financial Designs Inc. ADV now owns 35,280 shares of the company’s stock worth $108,000 after purchasing an additional 17,475 shares during the period. Capstone Investment Advisors LLC acquired a new position in shares of G1 Therapeutics during the fourth quarter valued at about $76,000. Finally, Jump Financial LLC bought a new stake in shares of G1 Therapeutics in the fourth quarter valued at about $105,000. 24.21% of the stock is owned by institutional investors.

About G1 Therapeutics

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.